FDA Approves Regeneron and Sanofi's Dupixent for Eczema

Regeneron Pharmaceuticals and Sanofi said they will charge $37,000 annually in the U.S. for their newly approved eczema drug, a price the companies said they reached after months of negotiations with pharmacy benefit managers.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: FREE Source Type: news
More News: Eczema | Pharmaceuticals